SCRIP
CITELINE COMMERCIAL

14 Aug 2022 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: what Amgen's $3.7bn ChemoCentryx buy means; Lilly's CEO on US drug pricing legislation; Pfizer's GBT acquisition; new data for Amgen's KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 August 2022, including: what *Amgen, Inc.*'s $3.7bn *ChemoCentryx, Inc.* buy means; *Eli Lilly and Company*'s CEO on US drug pricing legislation; *Pfizer Inc.*'s *Global Blood Therapeutics, Inc.* acquisition; new data for Amgen's KRAS inhibitor combo; and a major China ADC alliance for *Sanofi*.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Amgen's $3.7bn ChemoCentryx Buy May Help Offset Growing Pains*" - Scrip, 4 Aug, 2022.)

(Also see "*As Lilly's Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan*" - Scrip, 4 Aug, 2022.)

(Also see "*Pfizer's Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise*" - Scrip, 8 Aug, 2022.)

(Also see "*Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?*" - Scrip, 8 Aug,

© Citeline 2024. All rights reserved.

2022.)

(Also see "*Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge*" - Scrip, 5 Aug, 2022.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.